Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Sample Size Calculation01:19

Sample Size Calculation

3.2K
Knowledge of the sample size is the first requirement to conduct random sampling or an experiment. The sample size is the total number of units, observations, or groups (in some cases) used to get the data to estimate a population parameter. As the name suggests, the sample size is that of the sample drawn from the population and differs from the population size.
The sample size for the given experiment or sampling effort is fundamental to any study design. Sample size decides the number of...
3.2K
Margin of Error01:27

Margin of Error

3.9K
The margin of error is also called the maximum error of an estimate. The margin of error is the maximum possible or expected difference between the observed sample parameter value and the actual population parameter value. For proportion, it is the maximum difference between the value of sample proportion obtained from the data and the true value of population proportion. As the true value of the population parameter is not known, the margin of error is calculated using the sample statistic.
3.9K
Estimating Population Mean with Unknown Standard Deviation01:22

Estimating Population Mean with Unknown Standard Deviation

7.6K
In practice, we rarely know the population standard deviation. In the past, when the sample size was large, this did not present a problem to statisticians. They used the sample standard deviation s as an estimate for σ and proceeded as before to calculate a confidence interval with close enough results. However, statisticians ran into problems when the sample size was small. A small sample size caused inaccuracies in the confidence interval.
William S. Gosset (1876–1937) of the...
7.6K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

110
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
110
Testing a Claim about Standard Deviation01:19

Testing a Claim about Standard Deviation

2.4K
A complete procedure to test a claim about population standard deviation or population variance is explained here.
The hypothesis testing for the claim of population standard deviation (or variance) requires the data and samples to be random and unbiased. The population distribution also must be normal. There is no specific requirement on the sample size as the estimation is based on the chi-square distribution.
As a first step, the hypothesis (null and alternative) concerning the claim about...
2.4K
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

52
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
52

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early antiretroviral therapy and long-term cancer risk in HIV: 9-year outcomes from the START randomized trial.

BMC cancer·2026
Same author

Combined multi-omics and multi-spectral profiling of plasma extracellular vesicles reveals liquid biopsy biomarkers for glioma diagnosis.

Cell reports. Medicine·2026
Same author

Early Versus Delayed Anticoagulation in Acute Ischemic Stroke According to Atrial Fibrillation Subtype and Time of Diagnosis: Subgroup Analysis of the OPTIMAS Randomized Controlled Trial.

Stroke·2026
Same author

A Phase II Trial of Olaparib plus Pembrolizumab in Patients with Recurrent Copy Number-High/p53-Abnormal Endometrial Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Transdermal Estradiol Patches in Locally Advanced Prostate Cancer.

The New England journal of medicine·2026
Same author

Age-Related Germline Landscape of Endometrial Cancer: Focus on Early-Onset Cases.

JCO precision oncology·2026

Related Experiment Video

Updated: May 22, 2025

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
00:04

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.6K

Sample Size Calculation in Dose Optimization Trials Using the Margin of Practical Non-Inferiority.

Hakim-Moulay Dehbi1, Sean Devlins2, Alexia Iasonos2

  • 1Comprehensive Clinical Trials Unit, University College London, London, UK.

Statistics in Medicine
|May 19, 2025
PubMed
Summary
This summary is machine-generated.

This study introduces a practical non-inferiority framework for oncology dose optimization trials. It enables reduced sample sizes by considering efficacy, side effects, and quality-of-life for dose reduction strategies.

Keywords:
dosedose optimizationdose reductionrandomized trialsample size calculation

More Related Videos

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

8.2K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.0K

Related Experiment Videos

Last Updated: May 22, 2025

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
00:04

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.6K
E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

8.2K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.0K

Area of Science:

  • Oncology
  • Clinical Trial Design
  • Pharmacology

Background:

  • Dose optimization trials in oncology are crucial for modern therapeutics.
  • Efficacy may not linearly correlate with dose for novel agents.
  • Conventional non-inferiority trials require large, often unfeasible, sample sizes in Phase IV.

Purpose of the Study:

  • To propose and define a margin of practical non-inferiority for oncology dose optimization.
  • To demonstrate how this margin can justify smaller sample sizes.
  • To provide a framework for assessing dose reduction benefits beyond efficacy.

Main Methods:

  • Defining a margin of practical non-inferiority.
  • Pre-specifying additional dimensions (receptor occupancy, side effects, quality-of-life) for decision-making.
  • Comparing efficacy based on observed difference, not confidence intervals, to reduce sample size.

Main Results:

  • The proposed framework allows for justification of smaller sample sizes in dose optimization trials.
  • Reduced sample size is compensated by incorporating multiple dimensions into the assessment.
  • The method facilitates a more comprehensive evaluation of dose reduction potential.

Conclusions:

  • A practical non-inferiority approach offers a feasible alternative to conventional methods for oncology dose optimization.
  • This framework supports evidence-based dose reduction, potentially improving patient adherence and quality-of-life.
  • The strategy allows for a thorough assessment of dose reduction benefits in clinical practice.